A dose finding design for seizure reduction in neonates
Résumé
Clinical trials in vulnerable populations are extremely difficult to conduct. A sequential phase I–II trial aimed at finding the appropriate dose of levetiracetam for treating neonatal seizures was planned with a maximum sample size of 50 newborns. Three primary outcomes are considered: efficacy and two types of toxicity that occur at the same time but are measured at different time points. In the case of failure, physicians could add a second agent as a rescue medication.The primary outcomes were modelled via a logistic model for efficacy and a weighted likelihood with pseudo-outcomes for the two toxicities taking into account the dependences under Bayesian inference. Simulations were conducted to assess the design properties.
Fichier principal
WRAP-dose-finding-design-seizure-neonates-Stallard-2018.pdf (951.14 Ko)
Télécharger le fichier
Origine | Fichiers éditeurs autorisés sur une archive ouverte |
---|